Elunetirom
Small molecule
Also known as ABX-002
Evidence outlook
Major Depressive Disorder: mid-stage studies underway, no completed readout
In Major Depressive Disorder, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.
Also in development:Bipolar Disorder · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
AMPLIFY NCT06633016 · Major Depressive Disorder Registry: NCT06633016 | 2 | Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17) (6 weeks) 2026-06 | In progress: primary completion was expected 1 Jun 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Thyroid hormone receptor-beta drugs
Resmetirom, ALG-055009, VK2809, ASC47. Compare all 5 Thyroid hormone receptor-beta drugs
4 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Bipolar Disorder: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Elunetirom: this drug | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | Partial signal | Featured results are non-efficacy only in this race | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Olanzapine / Samidorphan (Lybalvi) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Resmetirom (Rezdiffra) | Approved(overall) | Small molecule | Thyroid hormone receptor-beta | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal Consta) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziprasidone | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| ALG-055009 | Phase 2(overall) | Small molecule | Thyroid hormone receptor-beta | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| VK2809 | Phase 2(overall) | Small molecule | Thyroid hormone receptor-beta | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1042 | Phase 1(overall) | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ASC47 | Phase 1(overall) | Small molecule | Thyroid hormone receptor-beta | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify MyCite) | Discontinued | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent